Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women

American Journal of Clinical Nutrition

Volumn 79, Issue 1, 2004, Pages 22-30

  Tiikkainen, Mirja ^a   Bergholm, Robert ^a,c   Rissanen, Aila ^a   Aro, Antti ^b   Salminen, Irma ^b   Tamminen, Marjo ^a   Teramo, Kari ^a   Yki Järvinen, Hannele ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

Diet; Fat intake; Fatty acids; Nutrition; Visceral fat

Indexed keywords

FATTY ACID; GAMMA LINOLENIC ACID; INSULIN; PHOSPHOLIPID; PLACEBO; TETRAHYDROLIPSTATIN;

AGE DISTRIBUTION; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FAT INTAKE; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; FUNCTION TEST; HUMAN; INSULIN CLAMP TECHNIQUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ABSORPTION; LIPID COMPOSITION; LOW CALORY DIET; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PHOSPHOLIPID BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS FAT; WEIGHT REDUCTION;

EID: 3242746341     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/79.1.22     Document Type: Article

References (64)

1. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 1991;40:280-9.
2. Rivellese AA, De Natale C, Lilli S. Type of dietary fat and insulin resistance. Ann N Y Acad Sci 2002;967:329-35.
3. Vessby B, Uusitupa M, Hermansen K, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia 2001;44:312-9.
4. Borkman M, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med 1993;328:238-44.
5. Decombaz J, Schmitt B, Ith M, et al. Postexercise fat intake repletes intramyocellular lipids but no faster in trained than in sedentary subjects. Am J Physiol Regul Integr Comp Physiol 2001;281:R760-9.
6. Bachmann OP, Dahl M, Brechtel K, et al. Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 2001;50:2579-84.
7. Jacob S, Machann J, Rett K, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999;48:1113-9.
8. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triacylglycerol levels are inversely related to insulin action. Diabetes 1997;46:983-8.
9. Krssak M, Falk PK, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999;42:113-6. (Published errata appear in Diabetologia 1999;42:386 and Diabetologia 1999;42:1269.)
10. Virkamäki A, Korsheninnikova E, Seppälä-Lindroos A, et al. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 2001;50:2337-43.
11. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001;50:1612-7.
12. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-5.
13. Sjoström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-72.
14. Vidgren HM, Agren JJ, Valve RS, Karhunen LJ, Rissanen AM, Uusitupa MI. The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. Clin Pharmacol Ther 1999;66:315-22.
15. Doucet E, St-Pierre S, Aimeras N, et al. Reduction of visceral adipose tissue during weight loss. Eur J Clin Nutr 2002;56:297-304.
16. Gower BA, Weinsier RL, Jordan JM, Hunter GR, Desmond R. Effects of weight loss on changes in insulin sensitivity and lipid concentrations in premenopausal African American and white women. Am J Clin Nutr 2002;76:923-7.
17. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999;48:839-47.
18. Purnell JQ, Kahn SE, Albers JJ, Kevin DN, Brunzell JD, Schwartz RS. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 2000;85:977-82.
19. Janssen I, Fortier A, Hudson R, Ross R. Effects of an energy-restrictive diet with or without exercise on abdominal fat, intermuscular fat, and metabolic risk factors in obese women. Diabetes Care 2002;25:431-8.
20. Weinsier RL, Hunter GR, Gower BA, Schutz Y, Darnell BE, Zuckerman PA. Body fat distribution in white and black women: different patterns of intraabdominal and subcutaneous abdominal adipose tissue utilization with weight loss. Am J Clin Nutr 2001;74:631-6.
21. Rossner S, Sjoström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:49-61.
22. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-42.
23. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6.
24. Dahl DB, Bachmann OP, Brechtel K, et al. Effects of orlistat (Xenical®) on insulin sensitivity (IS) in obese intentionally weight maintaining subjects. Diabetologia 2000;43:000 (abstr).
25. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862-8.
26. Trouillot TE, Pace DG, McKinley C, et al. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Am J Gastroenterol 2001;96:1888-94.
27. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Geneva: World Health Organization, 1999.
28. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
29. Ryysy L, Häkkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-58.
30. Sutinen J, Häkkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002;16:2183-93.
31. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985;41:810-7.
32. World Health Organization. Measuring obesity - classification and description of anthropometric data. Report on a WHO consultation on the epidemiology of obesity. Geneva: World Health Organization, 1987.
33. Miles J, Glasscock R, Aikens J, Gerich J, Haymond M. A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 1983;24:96-9.
34. Folch JS, Lees M, Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-507.
35. Stoffel W, Chu F, Ahrens EH Jr. Analysis of long-chain fatty acids by gas liquid chromatography. Anal Chem 1959;31:307-8.
36. Kadish AH, Hall DA. A new method for the continuous monitoring of blood glucose by measurement of dissolved oxygen. Clin Chem 1965;11:869-75.
37. Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971;33:732-8.
38. Stenman UH, Pesonen K, Ylinen K, Huhtala ML, Teramo K. Rapid chromatographic quantitation of glycosylated haemoglobins. J Chromatogr 1984;297:327-32.
39. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
40. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;69:1108-16.
41. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001;25:1713-21.
42. Mittendorfer B, Ostlund RE Jr, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599-604.
43. Tchernof A, Starling RD, Turner A, et al. Impaired capacity to lose visceral adipose tissue during weight reduction in obese postmenopausal women with the Trp64Arg beta 3-adrenoceptor gene variant. Diabetes 2000;49:1709-13.
44. Bouchard C, Tremblay A. Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins. J Nutr 1997;127:943S-7S.
45. Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997;82:727-34.
46. Gutin B, Barbeau P, Owens S, et al. Effects of exercise intensity on cardiovascular fitness, total body composition, and visceral adiposity of obese adolescents. Am J Clin Nutr 2002;75:818-26.
47. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91.
48. Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999;22:908-12.
49. Carey DG, Cowin GJ, Galloway GJ, et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obes Res 2002;10:1008-15.
50. Katoh S, Hata S, Matsushima M, et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - a randomized controlled trial. Metabolism 2001;50:414-7.
51. Riserus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. Int J Obes Relat Metab Disord 2001;25:1129-35.
52. Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a mechanism to improve energy balance and insulin resistance. Br J Nutr 2000;83(suppl):S59-S66.
53. Frayn KN. Visceral fat and insulin resistance - causative or correlative? Br J Nutr 2000;83(suppl):S71-7.
54. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-8.
55. Tiikkainen M, Tamminen M, Häkkinen AM, et al. Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 2002;10:859-67.
56. Greco AV, Mingrone G, Giancaterini A, et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002;51:144-51.
57. Vessby B, Tengblad S, Lithell H. Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia 1994;37:1044-50.
58. Ohrvall M, Berglund L, Salminen I, Lithell H, Aro A, Vessby B. The serum cholesterol ester fatty acid composition but not the serum concentration of alpha tocopherol predicts the development of myocardial infarction in 50-year-old men: 19 years follow-up. Atherosclerosis 1996;127:65-71.
59. Dougherty RM, Galli C, Ferro-Luzzi A, Iacono JM. Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: a study of normal subjects from Italy, Finland, and the USA. Am J Clin Nutr 1987;45:443-55.
60. Kris-Etherton PM, Yu S. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Am J Clin Nutr 1997;65(suppl):1628S-44S.
61. Andersson A, Nalsen C, Tengblad S, Vessby B. Fatty acid composition of skeletal muscle reflects dietary fat composition in humans. Am J Clin Nutr 2002;76:1222-9.
62. Luo J, Rizkalla SW, Vidai H, et al. Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care 1998;21:717-24.
63. McManus RM, Jumpson J, Finegood DT, Clandinin MT, Ryan EA. A comparison of the effects of n-3 fatty acids from linseed oil and fish oil in well-controlled type II diabetes. Diabetes Care 1996;19:463-7.
64. Rivellese AA, Maffettone A, Iovine C, et al. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 1996;19:1207-13.